Company News: Page (1) of 1 - 04/21/17 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook

EMD Serono and Merck KGaA, Darmstadt, Germany to Present Rebif® (interferon beta-1a) and Investigational Cladribine Tablets Data at AAN 2017

- Breadth of data and activities underscore company's long-standing commitment to enhancing care for people with MS (April 21, 2017)

ROCKLAND, Mass., April 21, 2017 /PRNewswire/ -- EMD Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, in the US and Canada, will present data at the American Academy of Neurology (AAN) 69th Annual Meeting, taking place from April 22-28, 2017, in Boston, Mass. EMD Serono and Merck KGaA, Darmstadt, Germany will present 15 abstracts on multiple sclerosis (MS), including studies evaluating Rebif® (interferon beta-1a) and investigational Cladribine Tablets.

"Rebif has a well-established safety profile supported by more than 20 years of accrued clinical trial and patient experience, and the information from the studies and analyses we are presenting at AAN deepens our understanding of this RRMS therapy," said Dr. Kathleen Hawker, Vice President, Neurology and Immunology US, EMD Serono.

The company will also present efficacy and safety data for Cladribine Tablets, an investigational short-course oral therapy that is thought to selectively and periodically target lymphocytes which may be integral to the pathological process of MS. Cladribine Tablets is currently under clinical investigation and not yet approved for the treatment for any use in the United States, Canada or elsewhere. In July 2016, the European Medicines Agency (EMA) accepted for review the Marketing Authorisation Application (MAA) of Cladribine Tablets for the treatment of adult patients with RRMS.


"We have an unwavering focus on delivering innovation to patients in need, and our presentations this week at AAN, a leading neurology conference, further validate the promise of Cladribine Tablets as a potential RRMS treatment option," said Luciano Rossetti, Head of Global R&D for the biopharma business of Merck KGaA, Darmstadt, Germany.

Attendees can learn more about EMD Serono's programs, pipeline and activities in neurology by visiting our medical booth #473. Booth activities include a $25,000 charitable donation presentation to Can DO MS on April 25 at 3 p.m. ET, as well as "I'm Facing MS" simulation stations that will translate users' experiences with different MS impairments into artwork.

AAN Brain Health Fair
EMD Serono will have an exhibition at the AAN Brain Health Fair on April 21 from 10 a.m. 4 p.m. ET, where attendees can gain first-hand experience about what it's like to have MS through virtual reality and other activities.

The following abstracts were accepted for presentation at the AAN 2017 Annual Meeting:

Rebif (interferon beta-1a) Presentations

Title

Lead Author

Abstract/
Poster #

Presentation Date/Time/Session

Cholecalciferol Supplementation in Relapsing Multiple Sclerosis Patients Treated with Subcutaneous Interferon Beta-1a: A Randomized Controlled Trial

 

W. Camu

004

 

April 27, 2017, 4:06 p.m.

 

Oral Presentation

Session S44: MS Risk Factors and Modifications

High Dose Cholecalciferol (Vitamin D3) Oil as Add-on Therapy in Subjects with Relapsing-Remitting Multiple Sclerosis Receiving Subcutaneous Interferon ß-1a (scIFN?-1a)

R. Hupperts

005

 

April 27, 2017, 4:18 p.m.

 

Oral Presentation

Session S44: MS Risk

 

Treatment with Interferon Reduces the Appearance of Lesions in Clinically Relevant White Matter (WM) Tracts in Patients with Clinically Isolated Syndrome (CIS)

 

M. Battaglini

 

340

 

April 28, 2017, 4:00 5:30 p.m.

 

Poster Session P6

Effect of Early Versus Delayed Treatment (DT) with Subcutaneous IFN ß-1a (scIFNß-1a) on Radiological Activity Free (RAF) or Clinical Activity Free (CAF) Status in Patients with Clinically Isolated Syndrome (CIS): A Post-hoc Analysis of REFLEXION

 

M. Freedman

358

 

April 28, 2017, 4:00 5:30 p.m.

 

Poster Session P6

 

Clinical Efficacy of Interferon ß-1a Subcutaneously Three Times Weekly According to Baseline Radiological Characteristics: Post Hoc Analyses of PRISMS Data

 

F. Nelson

343

April 28, 2017, 4:00 5:30 p.m.

 

Poster Session P6

Efficacy of Interferon ß-1a Subcutaneously Three Times Weekly According to Baseline EDSS/Duration, EDSS, and MSSS Sub-groups: Post Hoc Analysis of PRISMS Data

 

E. Williamson

329

 

April 28, 2017, 4:00 5:30 p.m.

 

Poster Session P6

 

Cladribine Tablets Presentations

Title

Lead Author

Abstract/
Poster #

Presentation Date/Time/Session

Cladribine Tablets in the Treatment of Patients with Multiple Sclerosis (MS): An Integrated Analysis of Safety from the MS Clinical Development Program

S. Cook

394

April 27, 2017, 5:30 7:00 p.m.

 

Poster Session P5

Absolute Lymphocyte Count Recovery in Patients with Relapsing-Remitting Multiple Sclerosis (RRMS) Treated with Cladribine Tablets 3.5 mg/kg in CLARITY and CLARITY Extension

 

P. Soelberg-Sorensen

379

 

April 27, 2017, 5:30 7:00 p.m.

 

Poster Session P5

Cladribine Tablets in the ORACLE-MS Study Open-label Maintenance Period: Analysis of Efficacy in Patients after Conversion to Clinically Definite Multiple Sclerosis (CDMS)

 

G. Comi

349

 

April 28, 2017, 4:00 5:30 p.m.

 

Poster Session P6

 

Defining High Disease Activity (HDA) in Patients with Relapsing Multiple Sclerosis (RMS) Receiving Placebo in the CLARITY Study

 

G. Giovannoni

351

April 28, 2017, 4:00 5:30 p.m.

 

Poster Session P6

Durable Efficacy of Cladribine Tablets in Patients with Multiple Sclerosis: Analysis of Relapse Rates and Relapse-free Patients in the CLARITY and CLARITY Extension Studies

 

G. Giovannoni

353

 

April 28, 2017, 4:00 5:30 p.m.

 

Poster Session P6

Efficacy of Cladribine Tablets 3.5 mg/kg in High Disease Activity (HDA) Subgroups of Patients with Relapsing Multiple Sclerosis (RMS) in the CLARITY Study

 

G. Giovannoni

360

April 28, 2017, 4:00 5:30 p.m.

 

Poster Session P6

Additional Company-Sponsored Presentations

Title

Lead Author

Abstract/
Poster #

Presentation Date/Time/Session

Multiple Sclerosis Relapse Rates, Before, During, and After Pregnancy: A US Retrospective Claims Database Analysis

 

A. Phillips

361

April 23, 2017, 4:00 5:30 p.m.

 

Poster Session P1

Pregnancy Complications of Women With and Without Multiple Sclerosis in a Large US Claims Database

 

M.K. Houtchens

110

April 24, 2017, 8:30 a.m. 7:00 p.m.

 

Poster Session P2

 

Does Patients' Experience of Care Differ by Level of Adherence in Multiple Sclerosis?

J. Smrtka

337

April 25, 2017, 5:30 7:00 p.m.

 

Poster Session P3

About Rebif® (interferon beta-1a)
Rebif (interferon beta-1a) is used to treat relapsing forms of MS to decrease the frequency of relapses and delay the occurrence of some of the physical disability that is common in people with MS. The efficacy and safety of Rebif in controlled clinical trials beyond 2-years has not been established.

Important Safety Information
Rebif is contraindicated in patients with a history of hypersensitivity to natural or recombinant interferon beta, human albumin, or any other component of the formulation.

Rebif should be used with caution in patients with depression, a condition that is common in people with multiple sclerosis. Depression, suicidal ideation, and suicide attempts have been reported to occur with increased frequency in patients receiving interferon compounds, including Rebif.

Severe liver injury, including some cases of hepatic failure requiring liver transplantation, has been reported rarely in patients taking Rebif. The potential for liver injury should be considered when used in combination with other products associated with liver injury.  Monitor liver function tests and patients for signs and symptoms of hepatic injury.  Consider discontinuing Rebif if hepatic injury occurs.

Anaphylaxis and other allergic reactions (some severe) have been reported as a rare complication of Rebif. Discontinue Rebif if anaphylaxis occurs.

In controlled clinical trials, injection site reactions occurred more frequently in Rebif-treated patients than in placebo-treated and Avonex-treated patients. Injection site reactions including injection site pain, erythema, edema, cellulitis, abscess, and necrosis have been reported in the postmarketing setting. Do not administer Rebif into affected area until fully healed; if multiple lesions occur, discontinue Rebif until skin lesions are healed.

Decreased peripheral blood counts in all cell lines, including pancytopenia, have been reported in Rebif-treated patients. In controlled clinical trials, leukopenia occurred at a higher frequency in Rebif-treated patients than in placebo and Avonex-treated patients. Thrombocytopenia and anemia occurred more frequently in 44 mcg Rebif-treated patients than in placebo-treated patients. Patients should be monitored for symptoms or signs of decreased blood counts. Monitoring of complete blood and differential white blood cell counts is also recommended.

Cases of thrombotic microangiopathy (TMA), some fatal, have been reported with interferon beta products, including Rebif, up to several weeks or years after starting therapy. Discontinue Rebif if clinical symptoms and laboratory findings consistent with TMA occur, and manage as clinically indicated.

Caution should be exercised when administering Rebif to patients with pre-existing seizure disorders. Seizures have been temporally associated with the use of beta interferons, including Rebif, in clinical trials and in postmarketing reports.

The most common side effects with Rebif are injection-site disorders, headaches, influenza-like symptoms, abdominal pain, depression, elevated liver enzymes, and hematologic abnormalities.

There are no adequate and well-controlled studies in pregnant women. Rebif should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Rebif full prescribing information is available at http://www.emdserono.com/ms.country.us/en/images/Rebif_PI_tcm115_140051.pdf?Version=

About Cladribine Tablets
Cladribine Tablets is an investigational short-course oral therapy that is thought to selectively and periodically target lymphocytes, which maybe integral to the pathological process of MS. Cladribine Tablets is currently under clinical investigation and not yet approved for the treatment for any use in the United States, Canada and Europe. In July 2016, the European Medicines Agency (EMA) accepted for review the Marketing Authorisation Application (MAA) of Cladribine Tablets for the treatment of relapsing remitting multiple sclerosis. 

The clinical development program for Cladribine Tablets includes:

  • The CLARITY (CLAdRIbine Tablets Treating MS OrallY) study and its extension: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of Cladribine Tablets as a monotherapy in patients with RRMS and its two-year extension designed to provide data on the long-term safety and efficacy of extended administration of Cladribine Tablets for up to four years.
  • The ORACLE MS (ORAl CLadribine in Early MS) study: a two-year Phase III placebo-controlled study designed to evaluate the efficacy and safety of Cladribine Tablets as a monotherapy in patients at risk of developing MS (patients who have experienced a first clinical event suggestive of MS).
  • The ONWARD (Oral Cladribine Added to Interferon beta-1a in Patients With Active Relapsing Disease) study: a Phase II placebo-controlled study designed primarily to evaluate the safety and tolerability of adding Cladribine Tablets treatment to patients with relapsing forms of MS, who have experienced breakthrough disease while on established interferon-beta therapy.
  • PREMIERE (Prospective Observational Long-term Safety Registry of Multiple Sclerosis Patients Who Have Participated in Cladribine Clinical Studies) study: interim long-term follow-up data from the prospective registry, PREMIERE, to evaluate the safety and efficacy of Cladribine Tablets. The follow-up will consist of over 10,000 patient years of exposure in total, with follow-up in some patients exceeding eight years at completion.

About Multiple Sclerosis
Multiple sclerosis (MS) is a chronic, inflammatory condition of the central nervous system and is the most common, non-traumatic, disabling neurological disease in young adults. It is estimated that approximately 2.3 million people have MS worldwide. While symptoms can vary, the most common symptoms of MS include blurred vision, numbness or tingling in the limbs and problems with strength and coordination. The relapsing forms of MS are the most common.

About EMD Serono, Inc.
EMD Serono is the North America biopharma business of Merck KGaA, Darmstadt, Germany - a leading science and technology company - focused exclusively on specialty care. For more than 40 years, the business has integrated cutting-edge science, innovative products and industry-leading patient support and access programs. EMD Serono has deep expertise in neurology, fertility and endocrinology, as well as a robust pipeline of potential therapies in oncology, immuno-oncology and immunology as R&D focus areas. Today, the business has more than 1,100 employees around the country with commercial, clinical and research operations based in the company's home state of Massachusetts.

www.emdserono.com

Your Contact
Alice McGrail       1-781-681-2886

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/emd-serono-and-merck-kgaa-darmstadt-germany-to-present-rebif-interferon-beta-1a-and-investigational-cladribine-tablets-data-at-aan-2017-300443408.html

SOURCE EMD Serono

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Shipping & Receiving, Sales & Marketing, Database, Other, Pro AV, Presentors, Computers/Peripherals, Business, Notebook/Laptop/Tablets, Marketing, Business Issues, Presentation, Marketing, People, Virtual Reality, Germany, Inc., Medicine, Disease, Pregnancy, Therapy, Surgery, Pregnancy, Science, Medical,
Related Sites: Digital Producer ,   Presentation Master ,   DMN Newswire ,   CEN - Notebooks ,   itbusinessnet.com ,   IBN - Business ,   VideoBasedTutorials ,   HTN - Health Technology Net ,   VRGamerNet
Related Newsletter: DMN Newsletter ,   CMN Newsletter ,   KNews Newsletter ,   Tutorial Finder ,   Review Seeker ,   IBN - IT Weekly Newsletter ,   DMN Newswire Newsletter ,   VRNewswire
HOT THREADS on DMN Forums

Our Privacy Policy --- @ Copyright, 2015 Digital Media Online, All Rights Reserved